Anemia treatment patterns in chronic kidney disease in pre-dialysis patients using darbepoetin alfa (NESP)

被引：0
|
作者：
Lunde, Martin
Fahrbach, Kyle
Nalysnyk, Luba
del Aguila, Michael
机构：
[1] Kidney Specialists Minnesota, Minneapolis, MN USA
[2] United Bio Source Corp, Medford, MA USA
[3] Roche Labs, Nutley, NJ USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2007年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
129
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [1] Epoetin alfa and darbepoetin alfa dosing patterns in anemic pre-dialysis chronic kidney disease patients
    Mody, S
    Padmanabhan, V
    McKenzie, RS
    Bookhart, B
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A96 - A96
  • [2] Epoetin alfa and darbepoetin alfa dosing patterns and drug costs in patients with pre-dialysis chronic kidney disease
    Lefevbre, P
    Mody, SH
    McKenzie, RS
    Bookhart, B
    Duh, MS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A39 - A39
  • [3] Epoetin alfa and darbepoetin alfa dosing trends in pre-dialysis chronic kidney disease patients
    Mody, S
    Padmanabhan, V
    McKenzie, S
    Piech, CT
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 416 - 416
  • [4] Epoetin alfa and darbepoetin alfa dosing trends and drug costs in elderly pre-dialysis chronic kidney disease patients
    Mody, S.
    Padmanabhan, V
    Bookhart, B.
    Mckenzie, R. S.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A12 - A13
  • [5] Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease
    Bradley A. Warady
    Mazen Y. Arar
    Gary Lerner
    Arline M. Nakanishi
    Catherine Stehman-Breen
    [J]. Pediatric Nephrology, 2006, 21 : 1144 - 1152
  • [6] Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease
    Warady, Bradley A.
    Arar, Mazen Y.
    Lerner, Gary
    Nakanishi, Arline M.
    Stehman-Breen, Catherine
    [J]. PEDIATRIC NEPHROLOGY, 2006, 21 (08) : 1144 - 1152
  • [7] Hospital inpatient utilization of epoetin alfa (EPO) and darbepoetin alfa (DARB) in patients with cancer and pre-dialysis chronic kidney disease (PCKD)
    Smith, J
    He, J
    Mahoney, A
    Noone, P
    Watson, S
    Mody, S
    McKenzie, RS
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A105 - A105
  • [8] HEMATOLOGIC OUTCOMES AND DOSING PATTERNS IN ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) SWITCHING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)
    Hura, Claudia
    Jackson, James
    Lunacsek, Orsolya
    Bailey, Robert A.
    McKenzie, R. Scott
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A65 - A65
  • [9] Anemia profile of pre-dialysis chronic kidney disease patients in India
    Vikrant, D. R. Sanjay
    [J]. NEPHROLOGY, 2008, 13 : A31 - A31
  • [10] OBSERVATIONAL STUDY OF ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) CONVERTING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)
    Lunde, Martin
    Jackson, James
    Lunacsek, Orsolya
    Bailey, Robert A.
    Senbetta, Mekre
    McKenzie, R. Scott
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A60 - A60
12345